Impact of osteopontin on the development of non-alcoholic liver disease and related hepatocellular carcinoma.

Alexander D NardoNicole G GrünMaximilian ZeydaMonika DumanicGeorg OberhuberElisa RivellesThomas H HelbichDaniel F MarkgrafMichael RodenThierry ClaudelMichael TraunerThomas M Stulnig

Published in: Liver international : official journal of the International Association for the Study of the Liver (2020)

Lack of osteopontin dissociates NASH-fibrosis severity from overall survival and HCC malignant transformation in NAFLD, and is therefore a putative therapeutic target only for advanced chronic liver disease.

Keyphrases

liver injury
drug induced
free survival